{
    "2020-07-21": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Novartis Stock Slips After Sales Miss Views On Coronavirus Impact",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Stock",
                        "Slips",
                        "Sales",
                        "Miss",
                        "Coronavirus",
                        "Impact"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "What's Behind Novartis' Disappointing Q2 Results",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Disappointing",
                        "Q2",
                        "Results"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "The Dow Is Up Because Europe Is Spending $2.1 Trillion on a Recovery Plan",
                "features": {
                    "keywords": [
                        "Dow",
                        "Up",
                        "Europe",
                        "Spending",
                        "Recovery",
                        "Plan"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "finance",
                        "economy"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Biogen to study Spinraza in combination with $2 mln Novartis drug",
                "features": {
                    "keywords": [
                        "Biogen",
                        "Spinraza",
                        "Novartis",
                        "drug",
                        "combination"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Novartis (NVS) Q2 Earnings Surpass Estimates, Sales Miss",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Q2",
                        "Earnings",
                        "Surpass",
                        "Estimates",
                        "Sales",
                        "Miss"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "mixed",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "mixed"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Novartis Stock Falls as Swiss Drugmaker Cuts Sales Outlook on Pandemic Woes",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Stock",
                        "Falls",
                        "Swiss",
                        "Drugmaker",
                        "Cuts",
                        "Sales",
                        "Outlook",
                        "Pandemic",
                        "Woes"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Is Amgen Stock A Buy As It Takes A Dual Approach To Targeting Coronavirus?",
                "features": {
                    "keywords": [
                        "Amgen",
                        "Stock",
                        "Buy",
                        "Dual",
                        "Approach",
                        "Targeting",
                        "Coronavirus"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "The Daily Biotech Pulse: Opko Wins CDC Contract, Novartis Lowers Guidance, Pieris Study Placed On Partial Clinical Hold",
                "features": {
                    "keywords": [
                        "Biotech",
                        "Opko",
                        "CDC",
                        "Contract",
                        "Novartis",
                        "Lowers",
                        "Guidance",
                        "Pieris",
                        "Study",
                        "Partial",
                        "Clinical",
                        "Hold"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Cocktails Boost Remy, Pandemic Disrupts Medicines: Earnings Wrap",
                "features": {
                    "keywords": [
                        "Cocktails",
                        "Boost",
                        "Remy",
                        "Pandemic",
                        "Disrupts",
                        "Medicines",
                        "Earnings",
                        "Wrap"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Novartis CEO Narasimhan on Growth Prospects, Pandemic Disruption",
                "features": {
                    "keywords": [
                        "Novartis",
                        "CEO",
                        "Narasimhan",
                        "Growth",
                        "Prospects",
                        "Pandemic",
                        "Disruption"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Novartis trims sales outlook after hit from COVID disruptions",
                "features": {
                    "keywords": [
                        "Novartis",
                        "trims",
                        "sales",
                        "outlook",
                        "COVID",
                        "disruptions"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Novartis tightens outlook as second-quarter sales, profit fall",
                "features": {
                    "keywords": [
                        "Novartis",
                        "tightens",
                        "outlook",
                        "second-quarter",
                        "sales",
                        "profit",
                        "fall"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Novartis delivered strong H1 performance. FY 2020 guidance confirmed at higher end for core operating income and lower end for sales.",
                "features": {
                    "keywords": [
                        "Novartis",
                        "strong",
                        "H1",
                        "performance",
                        "FY",
                        "2020",
                        "guidance",
                        "confirmed",
                        "core",
                        "operating",
                        "income",
                        "sales"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}